Supporting data for "Development of dual targeting powder formulations for inhalation delivery to both the upper and lower airways"

Dual targeting powder formulations of a small molecule antiviral tamibarotene were produced by spray drying (SD) and spray freeze drying (SFD). Factorial design was conducted using Minitab software to optimize the nasal SFD formulation. The powders were characterised by andersen cascade impactor (ACI), next generation impactor (NGI), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), laser diffraction, and dissolution study. A neutralising monoclonal antibody WKS13 was spray dried (SD) to produce dual targeting powder formulations and characterised by NGI, TGA, laser diffraction, antibody quantification (TAKE3), size exclusion chromatography (SEC), and gel electrophoresis (SDS-PAGE). In vivo antiviral studies were conducted by dual administration of WKS13 powders to both the lung and nasal cavity of hamsters against SARS-CoV-2 Delta variant. Finally, spray dried (SD) mannitol formulations containing stabilizing salts for radiolabeling was tested by TGA, laser diffraction and with a 3D-printed nasal replica coupled to the NGI.